u/sten_rautio

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.

long-acting amylin is the whole point of the molecule

Assumed the New Zealand position applied here. It does not, and someone corrected me politely with the actual source.

Which receptor family are you attributing that effect to?

amylin and GLP-1 are not redundant pathways

say which state only if it matters, but always say which country

nothing here is approved as a standalone product and research material is not for human use

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

Push back: the compounded arrangements changed and the advice you are quoting predates the change.

Small fix — amylin analogue, not a GLP-1 analogue.

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.

Disagree — that is registration status, and the question was about subsidy. Different decisions, different bodies.

phase 3 data will change most of what gets said here

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

Which receptor family are you attributing that effect to?

Agreed that the published criteria are the authority. They are searchable and most people never look.

Rang three pharmacies for a private price and got three different numbers, all in the same city.

Read the published criteria for my indication rather than asking. Twenty minutes, and it answered everything I had been guessing at.

private script pricing varies by pharmacy here too

a streamlined authority code is not the same as a general listing

Correction: that is the registration decision, not the subsidy listing. They are made by different bodies.

Cosigning on asking the pharmacy to check the wholesaler. It converts speculation into a fact in one phone call.

Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.

Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.

This.

Disagreeing with this bit: that advice predates the change in compounded arrangements.